|
Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer. |
| |
|
Research Funding - Bayer (Inst); Janssen (Inst); Medivation (Inst); Millennium (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - eviti |
| |
|
No Relationships to Disclose |
| |
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Sanofi |
| |
|
Consulting or Advisory Role - Astellas Pharma; Dendreon; Genomic Health |
Research Funding - Ambry Genetics (Inst); Bavarian Nordic (Inst); Johnson & Johnson (Inst); Sotio (Inst) |
| |
|
Employment - Visible Health |
Leadership - UrologyMatch |
Honoraria - Genomic Health |
Consulting or Advisory Role - Genomic Health |
Travel, Accommodations, Expenses - Genomic Health; Visible Health |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Endo Pharmaceuticals |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
| |
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
| |
|
No Relationships to Disclose |
| |
|
Patents, Royalties, Other Intellectual Property - patent pending |
| |
|
Consulting or Advisory Role - Astellas Pharma; Dendreon; Genentech; GlaxoSmithKline; Merck; Novartis |
Research Funding - Acceleron Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - Patent Pending (Inst) |